Shilpa Medicare launches generic anticancer drug Dasatinib

Shilpa Medicare Limited has informed the bourses that it has launched Indian branded generic of Dasatinib, an anticancer drug with a brand name ‘Dasashil’. The drug substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on April 12, 2020.

Dasashil is the first branded generic anti-cancer drug with all dosage strength of 20/50/70/100 mg tablets, used for the treatment of chronic myeloid leukaemia (CML).

Due to increased affordability, Dasashil will revolutionise the treatment by making it available for more and more Indian patients. The products are being manufactured and supplied from the state-of-the-art USFDA-approved manufacturing facility. At present, there are around 10,000 to 15,000 new patients of CML in India, which can be benefited by Dasashil tablets.

Presently, the monthly therapy cost of an innovator is approximately Rs 1.65 lakh. With the launch of Dasashil, the monthly cost of therapy will be drastically reduced to Rs 6,440.

Besides, recently, the company had received UK MHRA approval for Imatinib oral solution used for treating treatment cancer in pediatric and geriatric patients as well as patients with swallowing difficulties and also, offers dose titration across the patient population.

On Friday, the stock of Shilpa Medicare opened gap down by 3.4 per cent at Rs 381.15 from its previous close of Rs 394.55 on BSE. However, it later surged 2.6 per cent to Rs 405.